Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event

dc.contributor.authorTettey, Prudence
dc.contributor.authorSimpson, Steve
dc.contributor.authorTaylor, Bruce
dc.contributor.authorPonsonby, Anne-Louise
dc.contributor.authorLucas, Robyn
dc.contributor.authorDwyer, Terry
dc.contributor.authorKostner, Karam
dc.contributor.authorVan Der Mei, Ingrid
dc.date.accessioned2021-05-06T01:43:14Z
dc.date.issued2017
dc.date.updated2020-11-23T10:10:38Z
dc.description.abstractABSTRACT Objective To investigate the prospective associations between adiposity and lipid-related variables and conversion to multiple sclerosis (MS), time to subsequent relapse and progression in disability. Methods A cohort of 279 participants with a first clinical diagnosis of central nervous system demyelination was prospectively followed to 5-year review. Height, weight, waist and hip circumference were measured, and serum samples taken for measurement of lipids and apolipoproteins. Survival analysis was used for conversion to MS and time to relapse, and linear regression for annualised change in disability (Expanded Disability Status Scale). Results Higher body mass index (BMI; adjusted HR (aHR): 1.22 (1.04 to 1.44) per 5 kg/m2 increase), hip circumference (aHR: 1.32 (1.12 to 1.56) per 10 cm increase) and triglyceride levels (aHR: 1.20 (1.03 to 1.40) per unit increase) were associated with increased risk of subsequent relapse, while adiposity and lipid-related measures were not associated with conversion to MS. In addition, higher BMI (β: 0.04 (0.01 to 0.07) per 5 kg/ m2 increase), hip circumference (β: 0.04 (0.02 to 0.08) per 10 cm increase), waist circumference (β: 0.04 (0.02 to 0.07) per 10 cm increase), total cholesterol to highdensity lipoprotein ratio (TC/HDL ratio; β: 0.05 (0.001 to 0.10) and non-HDL; β: 0.04 (0.001 to 0.08) at study entry) were associated with a higher subsequent annual change in disability. Conclusions Higher levels of adiposity, non-HDL and TC/HDL ratio were prospectively associated with a higher rate of disability progression, and higher adiposity and triglycerides were associated with relapse but not with conversion to MS. Improving the lipid profile and losing weight into the healthy range could reduce the accumulation of disability.en_AU
dc.description.sponsorshipThe AusLong Study was funded by a grant from the Australian National Health and Medical Research Council (NHMRC APP544922) .en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn0022-3050en_AU
dc.identifier.urihttp://hdl.handle.net/1885/232487
dc.language.isoen_AUen_AU
dc.publisherBMJ Publishing Groupen_AU
dc.relationhttp://purl.org/au-research/grants/nhmrc/544922en_AU
dc.rights© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017.en_AU
dc.sourceJournal of Neurology Neurosurgery and Psychiatryen_AU
dc.titleAn adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating eventen_AU
dc.typeJournal articleen_AU
local.bibliographicCitation.issue5en_AU
local.bibliographicCitation.lastpage401en_AU
local.bibliographicCitation.startpage395en_AU
local.contributor.affiliationTettey, Prudence, University of Tasmaniaen_AU
local.contributor.affiliationSimpson, Steve, University of Tasmaniaen_AU
local.contributor.affiliationTaylor, Bruce, University of Tasmaniaen_AU
local.contributor.affiliationPonsonby, Anne-Louise, Murdoch Childrens Research Institute & University of Melbourneen_AU
local.contributor.affiliationLucas, Robyn, College of Health and Medicine, ANUen_AU
local.contributor.affiliationDwyer, Terry, Murdoch Children's Research Instituteen_AU
local.contributor.affiliationKostner, Karam, The University of Queenslanden_AU
local.contributor.affiliationVan Der Mei, Ingrid, University of Tasmania Menzies Research Instituteen_AU
local.contributor.authoruidLucas, Robyn, u4002313en_AU
local.description.embargo2099-12-31
local.description.notesImported from ARIESen_AU
local.identifier.absfor110104 - Medical Biochemistry: Lipidsen_AU
local.identifier.absfor111711 - Health Information Systems (incl. Surveillance)en_AU
local.identifier.absfor111706 - Epidemiologyen_AU
local.identifier.absseo920203 - Diagnostic Methodsen_AU
local.identifier.absseo920204 - Evaluation of Health Outcomesen_AU
local.identifier.absseo920111 - Nervous System and Disordersen_AU
local.identifier.ariespublicationa383154xPUB7001en_AU
local.identifier.citationvolume88en_AU
local.identifier.doi10.1136/jnnp-2016-315037en_AU
local.identifier.scopusID2-s2.0-85019028982
local.identifier.thomsonID000402734800108
local.publisher.urlhttp://jnnp.bmj.com/en_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Tettey_An_adverse_lipid_profile_and_2017.pdf
Size:
528.02 KB
Format:
Adobe Portable Document Format